Skip to content

Observation of the effect of Esketamine hydrochloride on saving opioid and improving anxiety and depression in patients with daytime thyroid cancer

Observation of the effect of Esketamine hydrochloride on saving opioid and improving anxiety and depression in patients with daytime thyroid cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069790
Enrollment
Unknown
Registered
2023-03-26
Start date
2023-03-25
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

Esketamine hydrochloride induced plus maintenance group:Esketamine hydrochloride 0.2mg/kg combined with sufentanil 0.2ug/kg in the induction period, and Esketamine hydrochloride 0.5mg/kg/h in the main
Esketamine hydrochloride maintenance group:Sufentanil 0.4ug/kg in induction period and Esketamine hydrochloride 0.5mg/kg in maintenance period
Traditional anesthesia group:Sufentanil 0.4ug/kg during induction and remifentanil (0.15-0.25)ug/kg/min during maintenance. Esketamine was not used

Sponsors

First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. General anesthesia for daytime thyroid cancer is proposed, ASA grade I-II 2. Age 18-65 3.BMI 18-30Kg/M2 4. Communication is normal 5. Volunteers and sign informed consent

Exclusion criteria

Exclusion criteria: 1.Unstable angina or myocardial infarction in the past six months, or a history of prior severe angina 2.Congestive heart failure 3.Elevated intracranial pressure and central nervous system damage 4.Have or have had a history of serious mental disorders 5.Increased intraocular pressure, glaucoma 6.Inability to understand visual analogue scale (VAS) 7.Inability to understand 15-item Quality of Recovery (QoR-15) 8. Inability to understand the Hospital Anxiety and Depression Scale (HADS) 9. Inability to understand the modified Brice questionnaire and Likert scale

Design outcomes

Primary

MeasureTime frame
Opioid use;Postoperative nausea and vomiting;Postoperative recovery quality scale 15 items;Hospital Anxiety and Depression Scale;Improved Brice questionnaire and Likert scale;

Secondary

MeasureTime frame
Ramsay sedation score;visual analogue scale;Postoperative ventilation time;blood sugar monitoring;Happiness and Satisfaction Survey;

Countries

China

Contacts

Public ContactChen Jingjing

First Affiliated Hospital of Anhui Medical University

1974512792@qq.com13956071075

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026